Study title:
Farah-R, Golomb-H-M, Hallahan-D-E, Desser-R-K, Griem-M-L, Blough-R, Ultmann-J-E, Weichselbaum-R-R.
Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, United States.
Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy.
International Journal of Radiation Oncology Biology Physics {INT-J- RADIAT-ONCOL-BIOL-PHYS}, 1989, Vol/Iss/Pg. 17/4 (761766), ISSN: 0360-3016.Farah-R, Golomb-H-M, Hallahan-D-E, Desser-R-K, Griem-M-L, Blough-R, Ultmann-J-E, Weichselbaum-R-R.
Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, United States.
Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy.
International Journal of Radiation Oncology Biology Physics {INT-J- RADIAT-...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|